Wegovy is a GLP-1 receptor agonist containing the active ingredient semaglutide, and it is approved in Japan as a treatment for obesity.
It helps reduce food intake by suppressing appetite and prolonging satiety, supporting effortless weight management.
Administered as a once-weekly subcutaneous injection, it is easy to continue, and when combined with diet and exercise, even greater weight loss effects can be expected.
Recommended for:
・Individuals diagnosed with obesity
・Those who want to suppress their appetite
・Those who want to diet effortlessly
・Those who prefer a once-weekly injection
・Those who have not achieved sufficient results with diet therapy alone
